Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Understanding the mechanisms underlying the remarkable beneficial effects of gastric bypass surgery is important for the development of non-surgical therapies or less invasive surgeries in the fight against obesity and metabolic disease. Although the intestinal L-cell hormones glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine (PYY) have attracted the most attention, direct tests in humans and rodents with pharmacological blockade or genetic deletion of either the GLP1-receptor (GLP1R) or the Y2-receptor (Y2R) were unable to confirm their critical roles in the beneficial effects gastric bypass surgery on body weight and glucose homeostasis. However, new awareness of the power of combinatorial therapies in the treatment of metabolic disease would suggest that combined blockade of more than one signaling pathway may be necessary to reverse the beneficial effects of bariatric surgery. METHODS: The metabolic effects of high-fat diet and the ability of Roux-en-Y gastric bypass surgery to lower food intake and body weight, as well as improve glucose handling, was tested in GLP1R and Y2R-double knockout (GLP1RKO/Y2RKO) and C57BL6J wildtype (WT) mice. RESULTS: GLP1RKO/Y2RKO and WT mice responded similarly for up to 20 weeks on high-fat diet and 16 weeks after RYGB. There were no significant differences in loss of body and liver weight, fat mass, reduced food intake, relative increase in energy expenditure, improved fasting insulin, glucose tolerance, and insulin tolerance between WT and GLP1RKO/Y2RKO mice after RYGB. CONCLUSIONS: Combined loss of GLP1R and Y2R-signaling was not able to negate or attenuate the beneficial effects of RYGB on body weight and glucose homeostasis in mice, suggesting that a larger number of signaling pathways is involved or that the critical pathway has not yet been identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity
Liou, A. P., Paziuk, M., Luevano, J.-M., Machineni, S., Turnbaugh, P. J., & Kaplan, L. M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005687 · Cited by 1,007 · cited 2×
“Thus, weight loss in this mouse model of RYGB is driven by both reduced energy intake and increased energy expenditure [34].”
BackgroundRoux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985
Long-term weight loss maintenance in the United States
Kraschnewski, J. L., Boan, J., Esposito, J., Sherwood, N. E., Lehman, E. B., Kephart, D. K., & Sciamanna, C. N. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.94 · Cited by 381 · cited 1×
“It is estimated that more than eighty percent of patients engaging in such non-invasive conventional weight loss therapies regain all lost body weight within a few years [2].”
BackgroundKorner, J., Bessler, M., Inabnet, W., Taveras, C., & Holst, J. J. (2007) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2007.08.004 · Cited by 344 · cited 1×
“GLP-1 and PYY, both secreted from the intestinal Lcells have attracted the most attention, because their postprandial circulating levels are greatly increased after both VSG and RYGB [7,8] and because they have powerful physiological actions on gut, pancreas, and brain that result in reduced food intake and lower body…”
BackgroundSvane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185 · cited 1×
“It is plausible that, when knocking out the GLP-1 signaling pathway, the PYY-signaling pathway takes over some of the functions and vice versa [16].”
Backgroundle Roux, C. W., Borg, C., Wallis, K., Vincent, R. P., Bueter, M., Goodlad, R., Ghatei, M. A., Patel, A., Bloom, S. R., & Aylwin, S. J. B. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181d3d21f · Cited by 176 · cited 3×
“There is ample evidence for hypertrophy and Lcell proliferation of the Roux and common limbs in rats [24,28,29] and as shown here in mice, the small and large intestine weights were significantly higher in mice with RYGB compared to sham surgery or weight-matching in both WT and GLP1RKO/Y2RKO mice, while all other org…”
BackgroundBaggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137
Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Chao, A. M., Alamuddin, N., Gruber, K., Leonard, S., Mugler, K., Bakizada, Z., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22359 · Cited by 116 · cited 1×
“More sustained effects are achieved with pharmacotherapy, particularly if combined with these conventional approaches [3], but the prospect that children and adolescents with obesity have to take drugs for decades is of concern.”
Background
Cited by
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Preclinical studies of metabolic surgery in mice with inactivation of PYY or its receptor yield conflicting results, with some supporting an important role for PYY in weight loss [103], yet others demonstrating that signaling through Y2R is dispensable for bariatric surgery-induced weight loss [104].”
ResultThe intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000612 · Cited by 42
Metadata
- Authors
- Boland, B. B., Mumphrey, M. B., Hao, Z., Townsend, R. L., Gill, B., Oldham, S., Will, S., Morrison, C. D., Yu, S., Münzberg, H., Rhodes, C. J., Trevaskis, J. L., & Berthoud, H.-R.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 25
- Pages
- 64-72
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W2944685885
- Cited by
- 36
- References
- 10
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.